Vaxcyte

Vaxcyte is a biopharmaceutical company dedicated to eliminating bacterial infections through the development of innovative vaccines. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine that aims to provide broader protection against invasive pneumococcal disease. Vaxcyte's approach involves re-engineering traditional vaccine production methods using advanced chemistry and synthetic techniques, including their proprietary XpressCF™ cell-free protein synthesis platform.